Loading…
Loading…
EQUITY / NASDAQ · XNCM
Enveric Biosciences Inc.
Following is saved. Automatic company research is not available for this coverage; explore the evidence with Research.
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →04/01/2026 – 06/30/2026 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗1.485 USD
Observed: 09/30/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
09/30/2026 · 1.485 USD · Volume 54,671
680 actual observations · Latest bar: 2026-09-30 · Market data is indicative; provider terms apply.
8 available financial reports
Research reports →SEC FINANCIAL REPORTS
04/01/2026 – 06/30/2026 · Units
| Metric | 2026 / Quarter 2 | 2025 / Quarter 2 | Change |
|---|---|---|---|
| Operating profit | -3,027,441 USD | -2,519,049 USD | — |
| Net income | -3,027,733 USD | -2,519,181 USD | — |
| Total equity | 8,082,524 USD | 2,184,769 USD | +269.95% |
| Total assets | 8,943,999 USD | — | — |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2026 / Quarter 204/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 06/30/2026ConsolidatedUnits · USD | 2026 / Quarter 201/01/2026 – 03/31/2026ConsolidatedUnits · USD | 2025 / Quarter 212/31/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Year end01/01/2025 – 12/31/2025ConsolidatedUnits · USD | 2025 / Quarter 307/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 301/01/2025 – 09/30/2025ConsolidatedUnits · USD | 2025 / Quarter 204/01/2025 – 06/30/2025ConsolidatedUnits · USD |
|---|---|---|---|---|---|---|---|---|
| Net incomeIncome statement | -3,027,733 USD | -4,661,206 USD | -1,633,473 USD | — | -8,771,987 USD | -1,873,669 USD | -6,577,816 USD | -2,519,181 USD |
| Operating profitIncome statement | -3,027,441 USD | -4,660,611 USD | — | — | -8,774,448 USD | -1,873,943 USD | -6,580,525 USD | -2,519,049 USD |
| Total assetsBalance sheet | 8,943,999 USD | — | — | 5,095,941 USD | 5,095,941 USD | 4,362,061 USD | — | — |
| Total equityBalance sheet | 8,082,524 USD | — | 5,060,788 USD | 4,177,541 USD | 4,177,541 USD | 3,456,176 USD | — | 2,184,769 USD |
| Financing cash flowCash flow statement | — | 8,348,207 USD | — | — | 10,579,507 USD | — | 7,890,361 USD | — |
| Operating cash flowCash flow statement | — | -4,701,378 USD | — | — | -8,141,543 USD | — | -6,356,680 USD | — |
| Report source | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 08/14/2026 | Open report ↗ Published: 03/27/2026 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 11/14/2025 | Open report ↗ Published: 08/14/2026 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.